Yarrow Bioscience prices $161.8M stock offering, expected to close Sept 14

Yarrow Bioscience, Inc. disclosed in a Form 8-K dated September 10, 2026 that it had entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the underwriters, to issue and sell 5,769,231 shares of common stock at a public offering price of $26.00 per share.¹

The company also granted the underwriters a 30-day option to purchase up to an additional 865,384 shares at the public offering price, less discounts and commissions, which the underwriters exercised in full on September 11, 2026.¹

With that option fully exercised, net proceeds from the offering are expected to be approximately $161.8 million, after deducting underwriters' discounts and commissions and estimated offering expenses.¹

The shares were sold under an existing shelf registration. According to the filing, the securities were offered pursuant to the company's shelf registration statement on Form S-3, as amended by Post-Effective Amendment No. 1, which the SEC declared effective on August 19, 2026.¹ The filing further notes that a final prospectus supplement dated September 10, 2026 was filed with the SEC on September 11, 2026.¹

As of the 8-K's filing, the offering was expected to close on September 14, 2026.¹ The document does not confirm that closing has actually occurred, only that it was anticipated for that date.

Separately, the company's directors and executive officers signed lock-up agreements agreeing not to sell or otherwise dispose of company common stock for 60 days after the date of the final prospectus supplement, subject to certain exceptions, without prior written consent from Jefferies LLC and TD Securities (USA) LLC.¹ The 8-K was signed on September 14, 2026 by Chief Executive Officer Rebecca Frey.